GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: American Journal of Medical Genetics Part A, Wiley, Vol. 158A, No. 11 ( 2012-11), p. 2700-2706
    Abstract: Noonan syndrome (NS) and Noonan‐like syndromes (NLS) are autosomal dominant disorders caused by heterozygous mutations in genes of the RAS/MAPK pathway. The aim of the study was to construct specific growth charts for patients with NS and NLS. Anthropometric measurements (mean of 4.3 measurements per patient) were obtained in a mixed cross‐sectional and longitudinal mode from 127 NS and 10 NLS patients with mutations identified in PTPN11 (n = 90), SOS1 (n = 14), RAF1 (n = 10), KRAS (n = 8), BRAF (n = 11), and SHOC2 (n = 4) genes. Height, weight, and body mass index (BMI) references were constructed using the lambda , mu , sigma (LMS) method. Patients had birth weight and length within normal ranges for gestational age although a higher preterm frequency (16%) was observed. Mean final heights were 157.4 cm [−2.4 standard deviation score (SDS)] and 148.4 cm (−2.2 SDS) for adult males and females, respectively. BMI SDS was lower when compared to Brazilian standards (BMI SDS of −0.9 and −0.5 SDS for males and females, respectively). Patients harboring mutations in RAF1 and SHOC2 gene were shorter than other genotypes, whereas patients with SOS1 and BRAF mutations had more preserved postnatal growth. In addition, patients with RAF1 and BRAF had the highest BMI whereas patients with SHOC2 and KRAS mutations had the lowest BMI. The present study established the first height, weight, and BMI reference curves for NS and NLS patients, based only on patients with a proven molecular cause. These charts can be useful for the clinical follow‐up of patients with NS and NLS. © 2012 Wiley Periodicals, Inc.
    Type of Medium: Online Resource
    ISSN: 1552-4825 , 1552-4833
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2012
    detail.hit.zdb_id: 1493479-6
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Hormone Research in Paediatrics, S. Karger AG, Vol. 80, No. 6 ( 2013), p. 449-456
    Abstract: 〈 b 〉 〈 i 〉 Aims: 〈 /i 〉 〈 /b 〉 To determine the presence of abnormal body proportion, assessed by sitting height/height ratio for age and sex (SH/H SDS) in healthy and short individuals, and to estimate its role in selecting short children for 〈 i 〉 SHOX 〈 /i 〉 analysis. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Height, sitting height and weight were evaluated in 1,771 healthy children, 128 children with idiopathic short stature (ISS), 58 individuals with 〈 i 〉 SHOX 〈 /i 〉 defects (SHOX-D) and 193 females with Turner syndrome (TS). 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The frequency of abnormal body proportion, defined as SH/H SDS 〉 2, in ISS children was 16.4% (95% CI 10-22%), which was higher than in controls (1.4%, 95% CI 0.8-1.9%, p 〈 0.001). The 〈 i 〉 SHOX 〈 /i 〉 gene was evaluated in all disproportionate ISS children and defects in this gene were observed in 19%. Among patients with SHOX-D, 88% of children (95% CI 75-100%) and 96% of adults had body disproportion. In contrast, SH/H SDS 〉 2 were less common in children (48%, 95% CI 37-59%) and in adults (28%, 95% CI 20-36%) with TS. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Abnormal body proportions were observed in almost all individuals with SHOX-D, 50% of females with TS and 16% of children considered ISS. Defects in 〈 i 〉 SHOX 〈 /i 〉 gene were identified in 19% of ISS children with SH/H SDS 〉 2, suggesting that SH/H SDS is a useful tool to select children for undergoing 〈 i 〉 SHOX 〈 /i 〉 molecular studies.
    Type of Medium: Online Resource
    ISSN: 1663-2818 , 1663-2826
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2013
    detail.hit.zdb_id: 2540224-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...